Inventor · disambiguated record
Richland Wayne Tester
Also filed as: TESTER RICHLAND · TESTER RICHLAND W · TESTER RICHLAND WAYNE
32 granted patents·8 pending applications·755 citations·filing 2001–2020
98Inventor score
Files withCELGENE AVILOMICS RES INC20CELGENE CAR LLC8SINGH JUSWINDER4SCIOS INC3AVILA THERAPEUTICS INC2
Top patents by PatentIndex Score
40 records- 0199US8609679B22,4-diaminopyrimidines useful as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2012·Granted Dec 17, 2013·84 cites·4 claims
- 0298US8710222B22,4-disubstituted pyrimidines useful as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2012·Granted Apr 29, 2014·52 cites·3 claims
- 0398US8450335B22,4-disubstituted pyrimidines useful as kinase inhibitorsSINGH JUSWINDER·Filed 2009·Granted May 28, 2013·130 cites·22 claims
- 0498US8338439B22,4-disubstituted pyrimidines useful as kinase inhibitorsSINGH JUSWINDER·Filed 2009·Granted Dec 25, 2012·175 cites·2 claims
- 0597US9987276B2Substituted 2,4-diaminopyrimidines as kinase inhibitorsCELGENE CAR LLC·Filed 2016·Granted Jun 5, 2018·23 cites·26 claims
- 0696US9212181B2Substituted 2,4-diaminopyrimidines as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2012·Granted Dec 15, 2015·34 cites·42 claims
- 0795US10010548B22,4-disubstituted pyrimidines useful as kinase inhibitorsCELGENE CAR LLC·Filed 2016·Granted Jul 3, 2018·15 cites·4 claims
- 0895US9409921B22,4-disubstituted pyrimidines as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2014·Granted Aug 9, 2016·25 cites·2 claims
- 0995US9296737B2Substituted 2,4-diaminopyrimidines as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2012·Granted Mar 29, 2016·27 cites·23 claims
- 1094US8563568B2Besylate salt of a BTK inhibitorWITOWSKI STEVEN RICHARD·Filed 2011·Granted Oct 22, 2013·46 cites·14 claims
- 1194US7989465B24,6-disubstituted pyrimidines useful as kinase inhibitorsAVILA THERAPEUTICS INC·Filed 2009·Granted Aug 2, 2011·26 cites·4 claims
- 1291US9604936B2Besylate salt of a BTK inhibitorCELGENE AVILOMICS RES INC·Filed 2013·Granted Mar 28, 2017·13 cites·14 claims
- 1390US11351168B12,4-disubstituted pyrimidines useful as kinase inhibitorsCELGENE CAR LLC·Filed 2020·Granted Jun 7, 2022·2 cites·3 claims
- 1490US10828300B2Substituted 2,4-diaminopyrimidines as kinase inhibitorsCELGENE CAR LLC·Filed 2018·Granted Nov 10, 2020·3 cites·27 claims
- 1590US10596172B22,4-disubstituted pyrimidines useful as kinase inhibitorsCELGENE CAR LLC·Filed 2018·Granted Mar 24, 2020·5 cites·3 claims
- 1690US9415049B2Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2013·Granted Aug 16, 2016·12 cites·27 claims
- 1790US8329901B24,6-disubstitued pyrimidines useful as kinase inhibitorsSINGH JUSWINDER·Filed 2011·Granted Dec 11, 2012·11 cites·5 claims
- 1890US7982036B24,6-disubstitued pyrimidines useful as kinase inhibitorsAVILA THERAPEUTICS INC·Filed 2008·Granted Jul 19, 2011·13 cites·12 claims
- 1989US9108927B2Salts of an epidermal growth factor receptor kinase inhibitorCELGENE AVILOMICS RES INC·Filed 2013·Granted Aug 18, 2015·9 cites·20 claims
- 2089US8748606B24,6-diaminopyrimidines useful as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2012·Granted Jun 10, 2014·8 cites·4 claims
- 2188US9540335B2Salts of an epidermal growth factor receptor kinase inhibitorCELGENE AVILOMICS RES INC·Filed 2015·Granted Jan 10, 2017·5 cites·20 claims
- 2288US8445498B24,6-disubstituted pyrimidines useful as kinase inhibitorsSINGH JUSWINDER·Filed 2011·Granted May 21, 2013·8 cites·17 claims
- 2385US10005738B2Salts of an epidermal growth factor receptor kinase inhibitorCELGENE CAR LLC·Filed 2017·Granted Jun 26, 2018·3 cites·20 claims
- 2485US9040541B24,6-disubstituted pyrimidines useful as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2013·Granted May 26, 2015·5 cites·24 claims
- 2584US9393246B24,6-disubstituted pyrimidines as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2015·Granted Jul 19, 2016·3 cites·11 claims
- 2682US10570099B2Salts of an epidermal growth factor receptor kinase inhibitorCELGENE CAR LLC·Filed 2018·Granted Feb 25, 2020·2 cites·22 claims
- 2777US9126950B2Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2013·Granted Sep 8, 2015·4 cites·24 claims
- 2874US11292772B2Salts of an epidermal growth factor receptor kinase inhibitorCELGENE CAR LLC·Filed 2020·Granted Apr 5, 2022·0 cites·14 claims
- 2973US9296704B2Substituted pyrimidines as protein kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2014·Granted Mar 29, 2016·1 cites·5 claims
- 3072US7220763B2Indole-type derivatives as inhibitors of p38 kinaseSCIOS INC·Filed 2003·Granted May 22, 2007·5 cites·32 claims
- 3172US6890938B2Indole-type inhibitors of p38 kinaseSCIOS INC·Filed 2001·Granted May 10, 2005·6 cites·28 claims
- 3258US2016311780A1Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2016·Application pending·0 cites
- 3357US2016279127A1Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2016·Application pending·0 cites
- 3451US2017095475A1Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2016·Application pending·0 cites
- 3549US2005171183A1Indole-type inhibitors of p38 kinaseSCIOS INC·Filed 2005·Application pending·0 cites
- 3647US2016030426A1Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2013·Application pending·0 cites
- 3743US2005288299A1Azaindole derivatives as inhibitors of p38 kinaseMAVUNKEL BABU J·Filed 2005·Application pending·0 cites
- 3842US9549927B2Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2015·Granted Jan 24, 2017·0 cites·25 claims
- 3941US2015216865A1Methods of treating a bruton's tyrosine kinase disease or disorderCELGENE AVILOMICS RES INC·Filed 2013·Application pending·0 cites
- 4040US2005065344A1Reagents for N-aminationFiled 2003·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →